Core Viewpoint - The article highlights the emergence of recombinant collagen as a significant anti-aging ingredient developed in China, marking a shift in the beauty industry where domestic brands gain authority in core raw materials, moving from a follower to a leader position in the global market [3][4][5]. Group 1: Company Overview - Marubi Biotech is one of the few companies in China that has achieved full-chain self-research and production of recombinant collagen, positioning itself as a representative of high-end beauty technology in the country [5][6]. - The company has played a crucial role in establishing national industry standards for recombinant collagen, transitioning from an industry participant to a standard setter, which signifies its technical authority [6][7]. Group 2: Technological Advancements - Marubi has developed a comprehensive research and production chain in the functional protein field, including gene editing, fermentation expression, structural verification, separation purification, and formula application [7][11]. - The establishment of the "National Recombinant Functional Protein Technology Research Center" under Marubi indicates its capability to not only serve its product development but also provide technical output to the industry [11][12]. Group 3: Product Development and Efficacy - Marubi's products, such as the "Recombinant Double Collagen," have achieved significant breakthroughs, including the first global production of high-activity recombinant human collagen through self-research and the use of translation pause technology [13][14]. - Clinical trials have shown that Marubi's products can effectively reduce wrinkle volume, with a reported 56.83% reduction in under-eye wrinkles and 13.18% in nasolabial folds after seven days of use [17][20]. Group 4: Market Strategy and Future Outlook - Marubi aims to establish a global presence by setting up research centers abroad and forming joint ventures, reflecting a shift from merely exporting products to a more comprehensive output of technology, standards, and brand culture [28][29]. - The company's vision includes creating a beauty standard that transcends cultural boundaries, emphasizing the importance of scientific research and long-term commitment to quality over short-term gains [28][30].

Investment Rating - The report suggests a focus on companies in the recombinant collagen sector, highlighting their potential for growth and market leadership [5][6]. Core Insights - Collagen is essential for human health, providing structural support and biological functions [11][14]. - The domestic recombinant collagen technology is advanced, with a complete industrial chain and supportive policies driving growth [6][31]. - The market for recombinant collagen is expected to grow significantly, with a projected CAGR of 41.4% from 2023 to 2027, surpassing the growth of animal-derived collagen [6][27]. - The applications of collagen are diverse, including medical aesthetics, skincare, intimate health, and hair health [6][33]. Summary by Sections 1. Collagen as a Vital Component - Collagen constitutes 30%-40% of human protein and is crucial for skin, bones, tendons, and ligaments [11][14]. - There are at least 29 types of collagen in the human body, with types I and III being the most common in the skin [14][15]. 2. Production: Recombinant vs. Animal-Derived Collagen - Recombinant collagen is produced using gene engineering, offering advantages such as no virus risk and better biocompatibility compared to animal-derived collagen [19][26]. - The market for recombinant collagen is expected to reach 286.3 billion yuan in 2023, with a significant growth trajectory [27][28]. 3. Policy Support for Market Development - The regulatory framework for recombinant collagen has been improving, with various guidelines issued since 2021 to standardize the industry [31][32]. 4. Diverse Applications of Recombinant Collagen - **Medical Aesthetics**: The market for recombinant collagen in medical aesthetics is projected to grow from 43 billion yuan in 2023 to 143 billion yuan by 2027, with a CAGR of 35.4% [6][42]. - **Skincare**: The market for functional skincare products containing recombinant collagen is expected to grow from 115 billion yuan in 2023 to 665 billion yuan by 2027, with a CAGR of 54.9% [47][49]. - **Intimate Health**: The market for intimate health products is anticipated to grow significantly, driven by increasing consumer awareness and demand [51][52]. 5. Key Companies in the Industry - **Jinbo Biological**: A leader in recombinant collagen with unique medical aesthetic products [5][40]. - **Juzi Biological**: Known for its brands Kefu Mei and Keli Jin, actively expanding its medical aesthetic pipeline [5][40]. - **Marubi Biological**: Accelerating its research in collagen, with significant product launches [5][40].